10-K/A - AN2 Therapeutics, Inc. (0001880438) (Filer)

Tue, May 14, 8:02 PM (73 days ago)

AN2 Therapeutics, Inc. filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The amendment addresses the omission of specific certification language in the originally filed Exhibits 31.1 and 31.2. These certifications pertain to the responsibilities of the Principal Executive Officer and Principal Financial Officer for establishing and maintaining internal control over financial reporting, as well as the design of such controls. This amendment does not update any other disclosures or reflect subsequent events post the original filing date. The company’s market value as of June 30, 2023, was approximately $108.7 million, with 29,770,375 shares outstanding as of March 22, 2024.